教育背景
1982年12月本科毕业于山东大学医学院医学系,并获得学士学位。2005年6月毕业于博士毕业于中国药科大学药理专业,并获理学博士学位
工作经历
项目课题经历
1、新型肿瘤多药耐药逆转剂HZ08与P-糖蛋白结合模式及转运机制研究,国家自然科学基金, 项目编号:81173088,起止时间:2012.01.—2015.12.,为项目主持人。到帐经费65万元。
2、基于肠道相关淋巴组织CD4+CD25+Foxp3+Treg细胞的灵仙新苷(AR)抗类风湿性关节炎的机制研究,2012年度教育部高等学校博士学科点专项科研基金(博导类),课题编号20120096110004,起止时间:2013.01.—2015.12.,为项目主持人。到帐经费12万元。
3、基于肠道粘膜免疫系统Treg细胞的抑炎作用揭示灵仙新苷抗康类风湿性关节炎的作用机制,江苏省高技术计划基金,项目编号:BY2014129。为项目主持人,到帐经费30万元。
4、1.1类创新药甲磺酸胺银内酯B片的临床研究,国家十三五重大专项“重大新药创制”(临床研究项目),编号:2016ZX09101-031,课题负责人。
5、 辛清感冒颗粒的研究,江苏省新药创制基金,项目编号:0512036,为项目主持人。已基本完成。项目起止年限:2005.12—2010.12.。到帐经费50万元。
6、 治疗类风湿性关节炎的中药一类新药AR6胶囊的临床前研究,江苏省高技术计划基金,项目编号:BG2007613。为项目主持人,项目起止年限:2007.08.—2010.12.。到帐经费40万元。
7、 新型抗风湿胶囊的研制,项目编号:BS96016. 起止时间:1996-1998年,江苏省科委社会发展基金,为项目主持人,已结题。项目起止年限:1996.10—1998.12.。到帐经费3万元。
8、 一种威灵仙新皂苷-Clematichinenoside AR抑制肿瘤坏死因子TNF-α活性的作用机制研究,国家自然科学基金, 项目编号:30772770,排名第二,负责药效学和活性测定.为该项目工作时间为4个月/每年.该部分内容已基本完成.。项目起止年限:2008.01.—2010.12.。到帐经费5万元。
9、灵仙新皂苷原料及胶囊,江苏省新药创制基金,项目编号:0709040。
排名第三。起止时间:2007.10.—2010.10.年,负责药效毒理试验。
10、中药一类新药灵仙新苷胶囊的研制,国家新药创制重大专项基金,(候选药物)项目编号:2009ZX09103-371,本人为项目副组长。到帐经费20万元。
11、多靶点抗脑缺血新药MA的研究与开发(化I类),国家科技重大专项“重大新药创制”(候选药物)(No.2009ZX09103-093),负责药效及机制研究,排名第二。到帐经费10万元。
12、一类抗高血压新药ATPT的研究,国家科技重大专项“重大新药创制”(临床前研究项目), 项目编号:2009ZX09102-036,到帐经费27万元。
13、逆转肿瘤多药耐药性HZ08药物研究,重大专项(化I类),国家科技重大专项“重大新药创制”(临床前研究项目), 项目编号:2002AA 233071,到帐经费15万元。
14、川阿格雷作用机制试验研究,国家十二五重大专项“重大新药创制”(临床前研究项目),编号:2012ZX09102101,该药效负责人。
15、抗肝癌新药CPUsiRNA2临床前研究(生物技术要一类),项目编号:2013ZX09301303005, 国家科技十二五重大专项“重大新药创制”(临床前研究项目),负责药效学研究,到帐经费6万元。
16、 逆转肿瘤多药耐药性HZ08药物研究,国家863计划基金,项目编号:2002AA 233071,起止时间:2002.01.—2005.01.年,负责药效试验,已结题。到帐经费3万元。
17、 重组水蛭素Ⅲ的新用途与新剂型研究,国家教育部博士点基金,项目编号:20040316005。起止时间:2004.03.—2006.12.年,负责药效毒理试验,目前已经完成。
18、 新型糖原磷酸化酶抑制剂科罗索酸及其衍生物的合成及生物活性研究,高等学校博士学科点基金,项目编号:Y071013。起止时间:2007.10.—2009.10.年,负责药效学及机制研究。到帐经费6万元。
19、教育部“2005年度新世纪优秀人才支持计划” 资助项目,项目编号:NCET-05-0495)。起止时间:2005.04.—2006.12.年,负责药效学及机制研究。
20、 酶工程技术研制L-麻黄素,课题编号:696-902-03-07,国家九五攻关项目,到帐经费:2万元。起止时间:1996.01.-2001.01.年,负责药效学及机制研究。
21、 银杏内酯的毒性研究,江苏省新药创制基金。起止时间:2002.01.至2005.12月,江苏吴中苏药医药开发有限责任公司。到帐经费9万元。
22、 川续断皂苷接骨胶囊研究,课题编号:96-901-05-65。起止时间:1996.09.-2001.09.国家新药研究基金,负责药效毒理试验。
23、糖原磷酸化酶抑制剂MA抗脑缺血研究,国家级创新性项目,指导老师:李运曼,国家教育部拨款:1万元。2007.01.-2008.01.。已结题。
论文、成果、著作等
1、Han D, Fang W, Zhang R, Wei J, Kodithuwakku ND, Sha L, Ma W1, Liu L, Li F, Li Y(通讯作者). Clematichinenoside protects blood brain barrier against ischemic stroke superimposed on systemic inflammatory challenges through up-regulating A20. Brain Behav Immun. 2016; 51: 56-69. (SCI,IF: 5.889)
2、Liu C, Du Q, Zhang X, Tang Z, Ji H, Li Y(通讯作者). Clematichinenoside Serves as a Neuroprotective Agent Against Ischemic Stroke: The Synergistic Action of ERK1/2 and cPKC Pathways. Front Cell Neurosci. 2016; 9:517.( SCI,IF:4.3)
3、Simin Yan a,b, Xu Zhang b, Haili Zheng b, Danhong Hu b, Yongtian Zhang b, Qinghua Guan b,Lifang Liu c, Qilong Ding b,n, Yunman Li(通讯作者)a,n,Clematichinenoside inhibits VCAM-1 and ICAM-1 expression in TNF-α-treated endothelial cells via NADPH oxidase-dependent IκB kinase/NF-κB pathway ,Free Radical Biology and Medicine 78 (2015) 190–201。(SCI,IF:5.71)
4、Huang J, Kodithuwakku ND, He W, Zhou Y, Fan W, Fang W, He G, Wu Q, Chu S, Li Y(通讯作者). The neuroprotective effect of a novel agent N2 on rat cerebral ischemia associated with the activation of PI3K/Akt signaling pathway. Neuropharmacology. 95 (2015): 12-21. (SCI,IF:5.106)
5、Fang W, Sha L, Kodithuwakku ND, Wei J, Zhang R, Han D, Mao L, Li Y(通讯作者). Attenuated Blood-Brain Barrier Dysfunction by XQ-1H Following Ischemic Stroke in Hyperlipidemic Rats. Mol Neurobiol. 2015; 52(1): 162-75. (SCI,IF: 5.137)
6、Yanyan Zhang a, Yidong Feng a, Kodithuwakku Nandani Darshika a, Bo Zhang a, Yahui Hu a, Weirong Fang a,Yunman Lia, (通讯作者), Wenlong Huang b,The effect of multidrug resistance modulator HZ08 onpharmacodynamics and pharmacokinetics of adriamycin in xenograft-nude mice. European Journal of Pharmaceutical Sciences 66 (2015) 109–117。(SCI,IF:3.005)
7、 Hu Z, Zhou Z, Hu Y, Wu J, Li Y(通讯作者), Huang W. HZ08 reverse P-glycoprotein mediated multidrug resistance in vitro and in vivo. PLoS One. 2015; 10(2): e0116886. ( SCI,IF:3.234)
8、Kodithuwakku ND, Feng YD, Zhang YY, Pan M, Fang WR, Li YM(通讯作者). The molecular insight into the antihyperuricemic and renoprotective effect of Shuang Qi gout capsule in mice. J Ethnopharmacol. 163 (2015): 278-89 (SCI,IF:3.055)
9、Weirong Fang, Rui Zhang, Lan Sha, Peng Lv, Erxin Shang, Dan Han, Jie Wei, Xiaohan Geng, Qichuan Yang, Yunman Li(通讯作者). Platelet activating factor induces transient blood-brain barrier opening to facilitate edaravone penetration into the brain. J Neurochem. (2014) 128, 662–671。(SCI,IF:3.973)
10、Yan-Yan Zhanga, Ya-Hui Hua, Yi-Dong Fenga, Kodithuwakku Nandani Darshikaa, Wei-Rong Fanga, Yun-Man Lia*(通讯作者), Wen-Long Huangb.The inhibitory and combinative mechanism of HZ08 with P-glycoprotein expressed on the membrane of Caco-2 cell line .Toxicology and Applied Pharmacology. 274(2014)232-239。(SCI,IF:3.973)
11、Xiong, Y., Ma, Y., Han, W., Kodithuwakku, N.D., Liu, L.F., Li, F.W., Fang, W.R., Li, Y.M i(通讯作者)., 2014. Clematichinenoside AR induces immunosuppression involving Treg cells in Peyers patches of rats with adjuvant induced arthritis. Journal of ethnopharmacology 2014. 155(2): 1306-14. (SCI,IF:2.755)
12、 Yi Zhou, Jinru Huang, Wei He, Wenxiang Fan, Weirong Fang, Guang-
wei He, Qiang Wu, Shaoxing Chu, Yunman Li(通讯作者),N2 ameliorates neural injury in experimental ischemic stroke via regulation of thromboxane A2 production. Pharmacology, Biochemistry and Behavior 124 (2014) 458–465. (SCI,IF:2.82)
13、 Weirong Fanga, 1, Jie Weia, 1, Dan Hana, Xi Chena, Guangwei Heb, Qiang Wub, Shaoxing Chub, Yunman Li(通讯作者),MC-002 exhibits positive effects against platelets aggregation and endothelial dysfunction through thromboxane A2 inhibition. Thrombosis Research,133(2014)610-615.(SCI,IF:2.427)。
14、Kodithuwakku, N.D., M. Pan, Y.L. Zhu, Y.Y. Zhang, Y.D. Feng, W.R. Fang, and Y.M. Li(通讯作者), Anti-inflammatory and antinociceptive effects of Chinese medicine SQ gout capsules and its modulation of pro-inflammatory cytokines focusing on gout arthritis. J Ethnopharmacol, 2013. 150(3): p. 1071-9.(SCI,IF:2.936)
15、Weirong Fang, Peng Lv, Xiaohan Geng, Erxin Shang, Qichuan Yang, Lan Sha, Yunman Li(通讯作者).. Penetration of verapamil across blood brain barrier following cerebral ischemia depending on both paracellular pathway and P-glycoprotein transportation. Neurochem Int. 62 (2013) 23–30 . (SCI,IF:2.857)。
16、Yidong Feng a, Yahui Hu a, Juan Cen a, Kodithuwakku Nandani Darshika a, Weirong Fang a,Yunman Lia*(通讯作者), Wenlong Huang b. HZ08 inhibits the multi-drug resistance on multiple sites as the substrate of p-glycoprotein. European Journal of Pharmacology 712 (2013) 53–59.(SCI,IF:2.592)。
17、Yan Qia, Jing-Yan Geb, Yi-Nan Wangc ,Hai-Yan Liub, Yun-Man Lia*(通讯作者), Zhong-Hui Liub,∗, Xue-Ling Cuib,∗ Co-expression of activin receptor-interacting protein 1 and 2 in mouse nerve cells. Neuroscience Letters 542 (2013) 53– 58. (SCI,IF:2.026)
18、Yi-dong Feng, Wei-rong Fang,Yun-man Li(通讯作者). HZ08 inhibits the multi-drug resistance on multiple sites as the substrate of p-glycoprotein. [J]. Acta Pharmacol Sin,Vol.34,Supplement July 2013. (SCI,IF:2.51)
19、Weirong Fang, Peng Lv, Xiaohan Geng, Erxin Shang, Qichuan Yang, Lan Sha, Yunman Li(通讯作者).. Penetration of verapamil across blood brain barrier following cerebral ischemia depending on both paracellular pathway and P-glycoprotein transportation. Neurochem Int. 62 (2013) 23–30 . (SCI,IF:2.857)。
20、Wei J, Fang W, Sha L, Han D, Zhang R, Hao X, Li Y(通讯作者). XQ-1H Suppresses Neutrophils Infiltration and Oxidative Stress Induced by Cerebral Ischemia Injury Both In Vivo and In Vitro. Neurochem Res. 2013; 38: 2542-2549 (SCI,IF:2.551)
21、Yi-dong Feng, Wei-rong Fang,Yun-man Li(通讯作者). HZ08 inhibits the multi-drug resistance on multiple sites as the substrate of p-glycoprotein. [J]. Acta Pharmacol Sin,Vol.34,Supplement July 2013. (SCI,IF:2.51)
22、Qian, Yisong, Guan, Teng, Huang, Menghao, Cao, Liangxun, *Li, Yunman(通讯作者), Cheng, Hao, Jin, Hangxia, Yu, Deyue,Neuroprotection by the soy isoflavone, genistein, via inhibition of mitochondria-dependent apoptosis pathways and reactive oxygen induced-NF-kappa B activation in a cerebral ischemia mouse model[J],Neurochemistry International, 60(8), pp 759-767, 2012/6. (SCI,IF:2.857)
23、Jing Xiong a,b,1, Li Baib,1, Wei Fang c, Jianyang Fu b, Weirong Fang b, Juan Cen b, Yi Kong d,*, Yunman Lib,* (通讯作者) . New peptide pENW (pGlu-Asn-Trp) inhibits platelet activation by attenuating Akt phosphorylation. European Journal of Pharmaceutical Sciences.45 (2012) 552–558. (SCI,IF:3.2)
24、Menghao Huang 1, Yisong Qian 1, Teng Guan 1, Longfei Huang, Xuzhen Tang, Yunman Li (通讯作者)*.Different neuroprotective responses of Ginkgolide B and bilobalide, the two Ginkgo. European Journal of Pharmacology 677 (2012) 71–76. (SCI,IF:2.516)
25、Qichuan Yang, Weirong Fang , Peng Lv, Xiaohan Geng ,Yunman Li* (通讯作者)Lan Sha. Therapeutic Neuroprotective Effects of XQ-1H in a Rat Model of Permanent Focal Cerebral Ischemia. Pharmacology 2012;89:1–6. (SCI,IF:1.82)
26、Y-L Zhu1,J Cen2, Y-Y Zhang 1 , Y-D Feng1, Y Yang1 , Y-M Li1*(通讯作者) , W-L Huang3. The Multidrug Resistant Modulator HZ08 Reverses Multidrug Resistance via P-glycoprotein Inhibition and Apoptosis Sensitization in Human Epidermoid Carcinoma Cell Line KBv200. Bibliography. February 16, 2012. (SCI,IF:0.82)
27、Jing Xiong1,2, Virginia M. Miller2,3*, Larry W. Hunter2, Yunman Li*(通讯作者), Muthuvel Jayachandran3. Leukocyte- and Platelet-Derived Microvesicle Interactions following In Vitro and In Vivo Activation of Toll-Like Receptor 4 by Lipopolysaccharide. PLoS ONE.September 2011 | Volume 6 | Issue 9.(SCI,IF:4.41)
28、Lv P, Fang W, Geng X, Yang Q, Li Y(通讯作者), Sha L. Therapeutic neuroprotective effects of ginkgolide B on cortex and basal ganglia in a rat model of transient focal ischemia. Eur J Pharm Sci. 2011; 44(3): 235-40 。IF 3.291(SCI,IF:3.291)
29、Zhen X, Cen J, Li YM(通讯作者), Yan F, Guan T, Tang XZ. Cytotoxic effect and apoptotic mechanism of tanshinone A, a novel tanshinone derivative, on human erythroleukemic K562 cells. Eur J Pharmacol. 2011; 667(1-3): 129-35.(SCI,IF:2.787)
30、Fang W, Geng X, Deng Y, Li Y(通讯作者), Shang E, Cen J, Lv P: Platelet activating factor induces blood brain barrier permeability alteration in vitro. J Neuroimmunol, 2011, 230(1-2):42-47. IF 2.98(SCI,IF:2.98)
31、Sun J, Li Y(通讯作者), Fang W, Mao L. Therapeutic time window for treatment of focal cerebral ischemia reperfusion injury with XQ-1h in rats. Eur J Pharmacol. 2011; 666(1-3): 105-10. (SCI,IF:2.787)
32、Longfei Huang a,1, Teng Guan a,1, Yisong Qian a,1, Yunman Lia(通讯作者), Hongbin Sun b.Anti-inflammatory effects of maslinic acid, a natural triterpene, in cultured cortical astrocytes via suppression of nuclear factor-kappa B. Eur J Pharmacol. 672 (2011) 169–174. (SCI,IF:2.787)
33、Perera PK, Peng C, Xue L, Li Y(通讯作者), Han C. Ex vivo and in vivo effect of Chinese herbal pill Yi Shen Juan Bi (YJB) on experimental arthritis. J Ethnopharmacol. 2011; 134(1): 171-5.. (SCI,IF:2.936)
34、Juan Cen, Yan Qi, Yunman Li(通讯作者), Weirong Fang, Yan Deng, Lu-yong Zhang, Wenlong Huang.HZ08, a great regulator to reverse multidrug resistance via cycle arrest and apoptosis sensitization in MCF-7/ADM. European Journal of Pharmacology. 2010; 647(1-3): 21-30. (SCI,IF:2.787)
35、Yan Deng, Weirong Fang, Yunman Li(通讯作者), Juan Cen, Fang Fang, Peng Lv, Shubo Gong, Lishun Mao. Blood-brain barrier breakdown by PAF and protection by XQ-1H due to antagonism of PAF effects. European Journal of Pharmacology, 2009, 616 (1-3): 43-47. (SCI,IF:2.787)
著作 :
1、李运曼、方伟蓉主编,《心血管药理学》,江苏科学技术出版社,南京2014年3月第一版。
2、丁启龙、李运曼主编,《生理学实验与指导》,(中英文对照)中国医药科技出版社,北京,2012年7月,第5次印刷。
2、刘耕陶主编《当代药理学》中国协和医科大学出版社出版,2008年5月出版,第二版,本人编写第35章神经系统药物作用的分子基础。(排名第一,3万字)。研究生用教材。
3、郭青龙主编,李运曼副主编,《人体解剖生理学》,中国医药科技出版社,北京,2009年8月,第一版。
4、楼宜嘉主编,李运曼副主编,《药物毒理理学》,人民卫生出版社,北京,2011年7月,第三版。
专利、著作版权等
申请专利共12项,其中第一发明人3项,第二发明人3项,第三发明人5项,第四发明人1项,第六发明人1项。
获发明专利证书10本:其中第一发明人3本,第二发明人1本,第三发明人5本,第四发明人1本。
声明:本站专家信息来源于各高校官网。